Sap Ag

Yale University

Ai Therapeutics, Inc.

Shanghai Yao Yuan Biotechnology Co., Ltd.

Shanghai United Imaging Healthcare Co., Ltd.

Lam Therapeutics, Inc.

Other

A1 Therapeutics, Inc.

Tian Xu

Sean Landrette

Jonathan Marc Rothberg

Henri Lichenstein

Neil Beeharry

Paul Beckett

Chris Conrad

Sophia Gayle

Tongruei Raymond Li

Xiaodong Chen

Wufan Tao

Danyang Liu

Dirk Saager

Weiyi Wang

Wan Yu

Cong Xu

Jieqing Fan

Andre Eichhorst

Yanfang Pan

Sheng Zhang

Eckhard Farrenkopf

Huaifang Jiang

Matt Dyer

Guanghui Chen

Spyridon Artavanis-Tsakonas

Ting Ye

Min Han

Kenji Matsuno

Xiaohui Wu

Marylens Hernandez

Simon Chen

Jing Cui

Robert J Diederich

Isabelle Busseau

Feng Qian

Eckhard Fakrenkopf

Fred Chen

Anna Zhang

Jay Xiong

The disclosure provides compositions and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen. The disclosure also provides heterocyclic compounds of formula (I) as agonists of alpha protein kinase 1 (ALPK1) and their use in activating ALPK1, modulating an immune response and treating diseases such as cancer, wherein A, A, L, L, L, Z, Z, W, W, R, R, R, R, R, Rand Rare defined herein.

Compositions and methods of modulating the immune response by activating alpha protein kinase 1

The present disclosure provides a collimator. The collimator includes a slice module, a filter module, and a support and protection module. The slice module and the filter module are detachably connected with the support and protection module. The rays strike on the collimator and pass through the slice module and the filter module in order. The slice module is configured to adjust the fan-beam width of the rays striking on the collimator. The filter module is configured to make the rays pass through different filters to implement different types of scanning.

Collimator of a scanning system

The present invention relates to methods for treating cancer with apilimod and related compositions and methods.

Apilimod compositions and methods for using same

The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.

Apilimod compositions and methods for using same in the treatment of renal cancer

The disclosure provides compositions and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen. The disclosure also provides heterocyclic compounds of formula (I) as agonists of alpha protein kinase 1 (ALPK1) and their use in activating ALPK1, modulating an immune response and treating diseases such as cancer, wherein A, A, L, L, L, Z, Z, W, W, R, R, R, R, R, Rand Rare defined herein. 

The present invention relates to the field of biotechnology, in particular to application of a GPR45 gene. The present invention discloses, for the first time, a correlation between GPR45 and obesity and also discloses that obesity may be caused if the GPR45 gene is knocked out or the expression of the GPR45 gene is reduced. Moreover, an obese mouse model is established by adopting a method of blocking the expression of the GPR45 gene for the first time, which is more similar to the mechanism underlying the obesity of human, is thus an ideal model for obesity basis and clinical application researches and can be well applied in screening of drugs for treating obesity.

Application of GPR45 gene

The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of 'low dose' HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.

Methods for treating cancer using HSP90 inhibitors

The present invention relates to methods for treating melanoma with apilimod and related compositions and methods.

Apilimod for use in the treatment of melanoma

The present disclosure relates to methods for preventing or treating a radiation-induced disease, disorder, or condition by administering apilimod to a subject in need thereof, and related compositions.

Compositions and methods relating to the radioprotective effects of apilimod

The present invention provides compositions and methods of using transposons. In one aspect, methods are disclosed that are useful for identifying negatively selected genes in an insertional mutagenesis screen. In another aspect, compositions for reducing proliferation of a tumor cell expressing an oncogenic RAS include an activator of a WNT pathway. Pharmaceutical compositions for reducing proliferation of tumor cells in a subject in need thereof by administering an effective amount of an activator of a WNT pathway to the tumor cells of the subject are also disclosed.

Compositions and methods of using transposons

Methods for treating cancer using apilimod

Apilimod for use in the treatment of renal cancer

Growing community of inventors

Shanghai, China

Tian Xu